Synapse

← BMJ Oncology

Papers in BMJ Oncology

Page 1 · newest first

  1. Investigating the determinants of immunotherapy response in the primary tumour of clear cell renal cell carcinoma (RCC)BMJ Oncology · 2026
  2. Looking inside the primary tumour: what drives immunotherapy response in renal cell carcinoma?BMJ Oncology · 2026
  3. Real-world effectiveness of NALIRIFOX versus modified FOLFIRINOX or gemcitabine and nab-paclitaxel in first-line advanced pancreatic adenocarcinoma: a multicentre propensity-matched studyBMJ Oncology · 2026
  4. Identification and management of genetic susceptibility to cancer: UK perspectiveBMJ Oncology · 2026
  5. Ovarian cancer diagnosis within 28 days after an emergency admission to hospital: national population-based study of patient risk factors and cancer characteristics using routinely collected data in EnglandBMJ Oncology · 2026
  6. Future of radiotheranosticsBMJ Oncology · 2026
  7. Impact of immune checkpoint inhibitors on pregnancy: current evidence and future directionsBMJ Oncology · 2026
  8. Ipsilateral recurrences after kidney-sparing surgery for upper tract urothelial carcinoma: a systematic review and meta-analysisBMJ Oncology · 2026
  9. Aligning awareness, systems and policy to increase equitable access to genomically driven cancer careBMJ Oncology · 2026
  10. Cytotoxic T-cell exhaustion analyses by in situ single-cell immunofluorescence in relation to colorectal cancer patient age, tissue bacteria and mortalityBMJ Oncology · 2026
  11. Incidence of new-onset depression after colorectal cancer diagnosis and associated mortality: a population-based cohort studyBMJ Oncology · 2026
  12. Optimising cancer immunotherapy and emerging data supporting de-escalation strategiesBMJ Oncology · 2026
  13. Active surveillance for a small low-risk papillary thyroid cancer: a 10-year prospective, observational study in an Italian tertiary care centreBMJ Oncology · 2026
  14. Screen-and-treat: a sustainable solution for cervical cancer elimination in low and middle income countriesBMJ Oncology · 2026
  15. Unveiling the variations in penile cancer care: identifying knowledge gaps and research prioritiesBMJ Oncology · 2026
  16. Correction for ‘Impact of loneliness on cancer mortality: a systematic review and meta-analysis’BMJ Oncology · 2026
  17. Treatment of oligometastatic lung cancers: new data, new drivers, new approachesBMJ Oncology · 2026
  18. Beyond a two-tier model: equitable molecular diagnostics for allBMJ Oncology · 2026
  19. Inequalities in cancer diagnostic outcomes for patients with a learning disability: a retrospective cohort study in EnglandBMJ Oncology · 2026
  20. Lost in translation: why genomic breakthroughs are not reaching patientsBMJ Oncology · 2026
  21. Foundation models in computational pathology: methods, applications and clinical implicationsBMJ Oncology · 2026
  22. Testicular cancer incidence and associations with prior epididymo-orchitis or urinary tract infections: a national cohort study in Sweden, 1964–2018BMJ Oncology · 2026
  23. CXCR4 in colorectal cancer: from prognostic marker to immunotherapy guide?BMJ Oncology · 2026
  24. Communicating clinical trial information about cancer drug products to patients and healthcare professionals: review of patient-reported outcome messagingBMJ Oncology · 2026
  25. Beyond the label: patient-reported outcomes and post-approval communication in oncologyBMJ Oncology · 2026
  26. Incident anaemia as a marker of cancer and all-cause mortality: evidence from 380 114 adults in the population-based Stockholm Early Detection of Cancer Study (STEADY-CAN) cohortBMJ Oncology · 2026
  27. Analgesic efficacy in women and men with cancer pain, treated with strong opioids: are there differences?BMJ Oncology · 2026
  28. World Radiotherapy Awareness Day: how we can make a differenceBMJ Oncology · 2026
  29. When herds overgraze: the cost of conformity in oncology drug developmentBMJ Oncology · 2026
  30. CXCR4 mRNA overexpression: an indicator of poor survival and predictor of response to immune checkpoint inhibitors in patients with metastatic colorectal cancerBMJ Oncology · 2026
  31. BASECAMP-1 screening study: a model for efficient enrolment in precision oncology clinical trialsBMJ Oncology · 2026
  32. Surgery as local consolidation therapy before progression in oncogene-driven stage IV NSCLC: a patient and advocacy perspectiveBMJ Oncology · 2026
  33. Circulating-tumour DNA (ctDNA) in NSCLC: mechanisms, evidence and the future of MRD detectionBMJ Oncology · 2026
  34. Rethinking cancer care in conflict settings: lessons from UkraineBMJ Oncology · 2026
  35. Impact of immunotherapy and small molecule cancer therapy on fertility: a narrative review of current evidence, mechanisms and future directionsBMJ Oncology · 2026
  36. Cancer care in wartime Ukraine: disruption, resilience and recoveryBMJ Oncology · 2026
  37. SAFFRON-301: a randomised phase III study of sitravatinib in combination with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancerBMJ Oncology · 2026
  38. Negative trial but positive lesson: reframing immunotherapy resistance from one-size-fits-all to precision strategiesBMJ Oncology · 2026
  39. Deficient mismatch repair/microsatellite instability-high colorectal cancer: current treatment paradigms, limitations and future perspectivesBMJ Oncology · 2026
  40. Human and financial consequences of herding in oncology drug development: clinical trials of TIGIT inhibitorsBMJ Oncology · 2026
  41. Bladder-sparing strategies for non-muscle-invasive bladder cancer after bacillus Calmette–Guérin failure: a systematic reviewBMJ Oncology · 2026
  42. Global determinants of cervical cancer outcomes: a health systems analysisBMJ Oncology · 2026
  43. Utilisation patterns of systemic anticancer therapy (SACT) in patients with advanced non-small cell lung cancer (NSCLC) in EnglandBMJ Oncology · 2026
  44. Bayesian networks as prognostic models in oncology: a systematic review and recommendations for clinical practiceBMJ Oncology · 2026
  45. Cost-effectiveness of neoadjuvant and adjuvant novel cancer therapies in stage II–III non-small cell lung cancer in Sri LankaBMJ Oncology · 2026
  46. Beyond auto-segmentation: the case for planning and dosimetry AI in head and neck radiation oncologyBMJ Oncology · 2026
  47. Beyond stage and HPV status: the evolving landscape and future of multidisciplinary deintensification in human papillomavirus-related oropharyngeal cancerBMJ Oncology · 2026
  48. Efficacy of nivolumab plus relatlimab versus BRAF/MEK inhibitors for first-line treatment of BRAF -mutant advanced melanoma: A matching-adjusted indirect comparisonBMJ Oncology · 2025
  49. Breast cancer awareness and breast self-examination among females in the Middle East and North Africa: a multinational cross-sectional studyBMJ Oncology · 2025
  50. Incidence of fractures in patients with solid cancers treated with immune checkpoint inhibitors: a systematic review and meta-analysis of randomised controlled trialsBMJ Oncology · 2025